Age-related macular degeneration 1 is associated with polymorphic variation in a gene at chromosomal locus 1q25.3-q31.1, per the disease definition in this packet. The condition is inherited in an autosomal dominant pattern, in which a single altered copy of the associated gene is sufficient to confer susceptibility. Specific gene data were not certified in the known_genes field of this packet despite the definition referencing a specific chromosomal locus.

Diagnosis involves ophthalmic examination with assessment of the macula, including fundoscopic evaluation and optical coherence tomography imaging. The presence of macular drusen is an obligate feature. The autosomal dominant inheritance documented in this packet is informative to the hereditary context of the condition.

No treatments specifically approved for age-related macular degeneration 1 are certified in this packet. No orphan drug designations for this specific condition are documented. Active clinical trials in the broader macular degeneration field are ongoing, with numerous studies examining investigational interventions.

Prognosis data specific to age-related macular degeneration 1 were not certified in this packet. The condition involves progressive macular changes with potential impact on central visual function. Individual outcomes vary based on the extent and progression of macular involvement.

Age-related macular degeneration 1 is associated with active clinical investigation in the broader macular degeneration field. Ongoing studies include Phase 2 trials of novel therapeutic agents (NCT07440225, EyeBiotech Ltd., recruiting; NCT07496567, EyeBiotech Ltd., recruiting) and a Phase 1 study of a cellular therapy for retinal degeneration (NCT07594236, Cellio Therapeutics, recruiting). Numerous additional trials are listed in the packet. Detailed trial information is accessible via ClinicalTrials.gov.